You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 264 No. 23, December 19, 1990 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens

J. P. Kane, M. J. Malloy, T. A. Ports, N. R. Phillips, J. C. Diehl and R. J. Havel
Cardiovascular Research Institute, University of California, San Francisco 94143-0130.

We conducted a randomized, controlled trial in 72 patients with heterozygous familial hypercholesterolemia to test whether reducing plasma low-density lipoprotein levels by diet and combined drug regimens can induce regression of coronary lesions. Four hundred fifty-seven lesions were measured before and after a 26-month interval by computer-based quantitative angiography. The primary outcome variable was within-patient mean change in percent area stenosis. Mean low-density lipoprotein cholesterol levels decreased from 7.32 +/- 1.5 to 4.45 +/- 1.6 mmol/L. The mean change in percent area stenosis among controls was +0.80, indicating progression, while the mean change for the treatment group was -1.53, indicating regression (P = .039 by two-tailed t test for the difference between groups). Regression among women, analyzed separately, was also significant. The change in percent area stenosis was correlated with low-density lipoprotein levels on trial. We conclude that reduction of low-density lipoprotein cholesterol levels can induce regression of atherosclerotic lesions of the coronary arteries in patients with familial hypercholesterolemia. The anticipation of benefit from treatment applies to women and men alike.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients
Pullinger et al.
J. Lipid Res. 2008;49:1846-1854.
ABSTRACT | FULL TEXT  

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton et al.
J Am Coll Cardiol 2008;51:1564-1572.
ABSTRACT | FULL TEXT  

Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko and King
Circulation 2008;117:560-568.
FULL TEXT  

New Technology for Noninvasive Evaluation of Coronary Artery Disease
Di Carli and Hachamovitch
Circulation 2007;115:1464-1480.
FULL TEXT  

Niaspan(R) in the management of dyslipidaemia: the evidence
Brown
Eur Heart J Suppl 2006;8:F60-F67.
ABSTRACT | FULL TEXT  

Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia
Aouizerat et al.
J. Lipid Res. 2006;47:787-793.
ABSTRACT | FULL TEXT  

Perspectives on Dyslipidemia and Coronary Heart Disease in Women
Bittner
J Am Coll Cardiol 2005;46:1628-1635.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Lovastatin Therapy in Adolescent Girls With Heterozygous Familial Hypercholesterolemia
Clauss et al.
Pediatrics 2005;116:682-688.
ABSTRACT | FULL TEXT  

Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy
Brown
Eur Heart J Suppl 2005;7:F34-F40.
ABSTRACT | FULL TEXT  

Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL
Albert et al.
J. Lipid Res. 2005;46:469-474.
ABSTRACT | FULL TEXT  

Apolipoprotein E Promotes the Regression of Atherosclerosis Independently of Lowering Plasma Cholesterol Levels
Raffai et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:436-441.
ABSTRACT | FULL TEXT  

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia
Meagher
J Am Board Fam Med 2004;17:424-437.
ABSTRACT | FULL TEXT  

Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review
Austin et al.
Am J Epidemiol 2004;160:407-420.
ABSTRACT | FULL TEXT  

Flavonoid-Rich Dark Chocolate Improves Endothelial Function and Increases Plasma Epicatechin Concentrations in Healthy Adults
Engler et al.
J. Am. Coll. Nutr. 2004;23:197-204.
ABSTRACT | FULL TEXT  

A Pedigree Analysis of Familial Hypercholesterolemia in Monozygote Twin Brothers
Li et al.
ANGIOLOGY 2003;54:711-713.
ABSTRACT  

Antioxidant Vitamins C and E Improve Endothelial Function in Children With Hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial
Engler et al.
Circulation 2003;108:1059-1063.
ABSTRACT | FULL TEXT  

Regression of Carotid and Femoral Artery Intima-Media Thickness in Familial Hypercholesterolemia: Treatment With Simvastatin
de Sauvage Nolting et al.
Arch Intern Med 2003;163:1837-1841.
ABSTRACT | FULL TEXT  

Cardiovascular Endocrinology: Introduction
Baxter et al.
Endocr. Rev. 2003;24:253-260.
FULL TEXT  

Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids
Aouizerat et al.
J. Lipid Res. 2003;44:1167-1173.
ABSTRACT | FULL TEXT  

Systematic Family Screening for Familial Hypercholesterolemia in Iceland
Thorsson et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:335-338.
ABSTRACT | FULL TEXT  

Long-term Compliance With Lipid-Lowering Medication After Genetic Screening for Familial Hypercholesterolemia
Umans-Eckenhausen et al.
Arch Intern Med 2003;163:65-68.
ABSTRACT | FULL TEXT  

Combination therapy: its rationale and the role of ezetimibe
Stone
Eur Heart J Suppl 2002;4:J19-J22.
ABSTRACT  

Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL
Cheung et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21:1320-1326.
ABSTRACT | FULL TEXT  

Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia
Bhatnagar et al.
BMJ 2000;321:1497-1497.
ABSTRACT | FULL TEXT  

Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis : The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)
Teo et al.
Circulation 2000;102:1748-1754.
ABSTRACT | FULL TEXT  

Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias
Fodor et al.
CMAJ 2000;162:1441-1447.
FULL TEXT  

Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury
Indolfi et al.
J Am Coll Cardiol 2000;35:214-221.
ABSTRACT | FULL TEXT  

Preventing Coronary Artery Disease by Lowering Cholesterol Levels: Fifty Years From Bench to Bedside
Steinberg and Gotto
JAMA 1999;282:2043-2050.
ABSTRACT | FULL TEXT  

Drug Treatment of Lipid Disorders
Knopp
NEJM 1999;341:498-511.
FULL TEXT  

Long-Term Follow-Up After Percutaneous Transluminal Coronary Angioplasty Was Not Performed Based on Intravascular Ultrasound Findings : Importance of Lumen Dimensions
Abizaid et al.
Circulation 1999;100:256-261.
ABSTRACT | FULL TEXT  

Effects of Lovastatin and Warfarin on Early Carotid Atherosclerosis : Sex-Specific Analyses
Byington et al.
Circulation 1999;100 :e14-e17.
ABSTRACT | FULL TEXT  

Improvement of Impaired Myocardial Vasodilatation Due to Diffuse Coronary Atherosclerosis in Hypercholesterolemics After Lipid-Lowering Therapy
Yokoyama et al.
Circulation 1999;100:117-122.
ABSTRACT | FULL TEXT  

Aggressive Cholesterol Lowering Delays Saphenous Vein Graft Atherosclerosis in Women, the Elderly, and Patients With Associated Risk Factors : NHLBI Post Coronary Artery Bypass Graft Clinical Trial
Campeau et al.
Circulation 1999;99:3241-3247.
ABSTRACT | FULL TEXT  

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile
Dangas et al.
J Am Coll Cardiol 1999;33:1294-1304.
ABSTRACT | FULL TEXT  

Forecasting Patient Outcomes in the Management of Hyperlipidemia
Brier et al.
Arch Intern Med 1999;159:569-575.
ABSTRACT | FULL TEXT  

Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions
Bucher et al.
Arterioscler. Thromb. Vasc. Bio. 1999;19:187-195.
ABSTRACT | FULL TEXT  

Strategies to achieve coronary arterial plaque stabilization
Rabbani and Topol
Cardiovasc Res 1999;41:402-417.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia: A Randomized Controlled Trial
Stein et al.
JAMA 1999;281:137-144.
ABSTRACT | FULL TEXT  

Present Status of HMG Reductase Inhibitors in Treatment of Dyslipidemia
Kalmansohn et al.
ANGIOLOGY 1998;49:801-805.
ABSTRACT  

Joint British recommendations on prevention of coronary heart disease in clinical practice
British Cardiac Society et al.
Heart 1998;80:1S-29.
FULL TEXT  

Effective Lipid Modification by Partial Ileal Bypass Reduced Long-term Coronary Heart Disease Mortality and Morbidity: Five-Year Posttrial Follow-up Report From the POSCH
Buchwald et al.
Arch Intern Med 1998;158:1253-1261.
ABSTRACT | FULL TEXT  

Angiotensin-Converting Enzyme DD Genotype and Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia
O'Malley et al.
Circulation 1998;97:1780-1783.
ABSTRACT | FULL TEXT  

Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis : Results of the LIPID Atherosclerosis Substudy
MacMahon et al.
Circulation 1998;97:1784-1790.
ABSTRACT | FULL TEXT  

IDL Composition and Angiographically Determined Progression of Atherosclerotic Lesions During Simvastatin Therapy
Sutherland et al.
Arterioscler. Thromb. Vasc. Bio. 1998;18:577-583.
ABSTRACT | FULL TEXT  

Treating Hyperlipidemia for the Primary Prevention of Coronary Disease: Are Higher Dosages of Lovastatin Cost-effective?
Perreault et al.
Arch Intern Med 1998;158:375-381.
ABSTRACT | FULL TEXT  

Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol
Frick et al.
Circulation 1997;96:2137-2143.
ABSTRACT | FULL TEXT  

Simvastatin Reduces Graft Vessel Disease and Mortality After Heart Transplantation : A Four-Year Randomized Trial
Wenke et al.
Circulation 1997;96:1398-1402.
ABSTRACT | FULL TEXT  

Single-strand conformation polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterolemia
Humphries et al.
Clin. Chem. 1997;43:427-435.
ABSTRACT | FULL TEXT  

Hypobetalipoproteinemia Is Associated With Low Levels of Hemostatic Risk Factors in the Framingham Offspring Population
Welty et al.
Circulation 1997;95:825-830.
ABSTRACT | FULL TEXT  

The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts
The Post Coronary Artery Bypass Graft Trial Invest
NEJM 1997;336:153-163.
ABSTRACT | FULL TEXT  

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia
Stein et al.
J CARDIOVASC PHARMACOL THER 1997;2:7-16.
ABSTRACT  

Serum Lipids and Incidence of Coronary Heart Disease: Findings From the Systolic Hypertension in the Elderly Program (SHEP)
Frost et al.
Circulation 1996;94:2381-2388.
ABSTRACT | FULL TEXT  

Predominance of Dense Low-Density Lipoprotein Particles Predicts Angiographic Benefit of Therapy in the Stanford Coronary Risk Intervention Project
Miller et al.
Circulation 1996;94:2146-2153.
ABSTRACT | FULL TEXT  

Effects of Cigarette Smoking on the Angiographic Evolution of Coronary Atherosclerosis: A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy
Waters et al.
Circulation 1996;94:614-621.
ABSTRACT | FULL TEXT  

The Influence of Angiographic Endpoints on the Outcome of Lipid Intervention Studies: A Proposal for Standardization
Wouter Jukema et al.
ANGIOLOGY 1996;47:633-642.
ABSTRACT  

Coronary Heart Disease Risk Factors in Men and Women Aged 60 Years and Older : Findings From the Systolic Hypertension in the Elderly Program
Frost et al.
Circulation 1996;94:26-34.
ABSTRACT | FULL TEXT  

LDL-Apheresis Atherosclerosis Regression Study (LAARS) : Effect of Aggressive Versus Conventional Lipid Lowering Treatment on Coronary Atherosclerosis
Kroon et al.
Circulation 1996;93:1826-1835.
ABSTRACT | FULL TEXT  

Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women
Guetta and Cannon
Circulation 1996;93:1928-1937.
FULL TEXT  

Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference?
Corson et al.
PERSPECT VASC SURG ENDOVASC THER 1996;9:75-94.
 

Progression of Coronary Artery Disease Predicts Clinical Coronary Events : Long-term Follow-up From the Cholesterol Lowering Atherosclerosis Study
Azen et al.
Circulation 1996;93:34-41.
ABSTRACT | FULL TEXT  

Hyperlipidemia and Coronary Disease : Correction of the Increased Thrombogenic Potential With Cholesterol Reduction
Lacoste et al.
Circulation 1995;92:3172-3177.
ABSTRACT | FULL TEXT  

Effects of Cholesterol Lowering on the Progression of Coronary Atherosclerosis in Women : A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy
Waters et al.
Circulation 1995;92:2404-2410.
ABSTRACT | FULL TEXT  

Kuopio Atherosclerosis Prevention Study (KAPS) : A Population-Based Primary Preventive Trial of the Effect of LDL Lowering on Atherosclerotic Progression in Carotid and Femoral Arteries
Salonen et al.
Circulation 1995;92:1758-1764.
ABSTRACT | FULL TEXT  

Effect of Pravastatin on Outcomes after Cardiac Transplantation
Kobashigawa et al.
NEJM 1995;333:621-627.
ABSTRACT | FULL TEXT  

Lipid Lowering, Regression, and Coronary Events : A Review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting
Gotto
Circulation 1995;92:646-656.
FULL TEXT  

The Primary Prevention of Coronary Heart Disease in Women
Rich-Edwards et al.
NEJM 1995;332:1758-1766.
FULL TEXT  

Management of Primary Hyperlipidemia
Havel and Rapaport
NEJM 1995;332:1491-1498.
FULL TEXT  

Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels : The Regression Growth Evaluation Statin Study (REGRESS)
Jukema et al.
Circulation 1995;91:2528-2540.
ABSTRACT | FULL TEXT  

Cholesterol Reduction in Cardiovascular Disease -- Clinical Benefits and Possible Mechanisms
Levine et al.
NEJM 1995;332:512-521.
FULL TEXT  

Coronary artery bypass grafting in familial hypercholesterolemia
Kawasuji et al.
J. Thorac. Cardiovasc. Surg. 1995;109:364-369.
ABSTRACT | FULL TEXT  

Reversal of Gangrenous Lesions in the Blue Toe Syndrome with Lovastatin A Case Report
Cabili et al.
ANGIOLOGY 1993;44:821-825.
ABSTRACT  

CHOLESTEROL REDUCTION AND REGRESSION OF CORONARY DISEASE
JWatch General 1991;1991:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.